The primary clinical goal in the treatment of PRL microadenomas is to preserve gonadal and reproductive function, and this goal is achieved significantly with drug therapy, i.e., the drugs are effective in controlling PRL levels, and with long-term effective DA therapy, microadenomas often shrink and sometimes disappear. Since only 5-10% of microadenomas progress to macroadenomas, control of tumor size is not the primary goal of drug therapy and women who do not want to have children can be treated without DA. Women who have stopped menstruating may receive estrogen therapy, but PRL levels should be evaluated periodically, including review of dynamic enhancement MRI to observe changes in tumor size.